PharmaEssentia

PV in Focus is almost here! ? If you or a loved one are living with #PolycythemiaVera (PV), join us on April 5th in Boston, MA. You'll hear from several speakers, gain tools for self-advocacy and managing mental health and PV, and connect with others. Breakfast and lunch will be served. ? Find the details and RSVP here: PVInFocus.com

Living with polycythemia vera comes with unique challenges, but no one has to navigate the journey alone. ? PV Pod: Stories from the Marrow brings together patient voices, expert insights, and real experiences to shed light on life with PV. ? ?? Listen now: https://lnkd.in/grzWFXwy

Cytokines offer tremendous therapeutic potential, but challenges like short half-life and toxicity have limited their use. ? Our pegylation approach is designed to enhance cytokine stability and improve tolerability—unlocking new possibilities in cancer and other diseases.

Looking to make a career move this spring? We’re hiring! ? Here are a few of our current open positions: ? ?? Senior Manager, Patient Access ?? Staff Accountant ?? Head of Sales ? Check out our career page to view our full list: https://lnkd.in/eE2HJxPX

On this International Women’s Day, we are especially proud to celebrate the brilliant #WomeninSTEM who are shaping the future of oncology, biotechnology, and patient care—breaking barriers, driving discoveries, and transforming lives around the world. ? #IWD2025

Have you heard of essential thrombocythemia (ET)? ? ET, like polycythemia vera (PV), is a myeloproliferative neoplasm that disrupts blood cell production. While PV causes excess red blood cells, ET results in elevated platelets, increasing the risk of clots, stroke, and other complications. ? Read more about ET, including risk factors and symptoms, from our partners at MPN Research Foundation: https://lnkd.in/e4-vRKxX

Today we share an important update for the polycythemia vera (PV) community: The latest NCCN Clinical Practice Guidelines in Oncology (Version 1.2025, January 21, 2025)—a trusted resource that informs treatment decisions for clinicians—now highlight that ropeginterferon alfa-2b-njft (BESREMi?) can be used as a substitution for treating PV in the event that peginterferon alfa-2a (Pegasys?) is unavailable. This guidance comes at a crucial time, as an ongoing shortage poses challenges in treatment continuity. Read more in our latest release: https://lnkd.in/efqx4_zt Find the updated NCCN guidelines here (Login required): https://lnkd.in/ejJGrKBG

As an industry leader in the MPN community, we are proud to support Rare Disease Day and show our stripes for the several thousands of people who have been diagnosed with an MPN. Join us as we help raise awareness for the 300 million worldwide who are living with a rare disease and to work towards equitable access to diagnosis, treatment, and care. #RareDiseaseDay #ShowYourStripes?

Finding Strength in the Journey: Patti’s Story ? After her polycythemia vera (PV) diagnosis, Patti struggled to adjust, pushing herself to maintain her active lifestyle. But with the unwavering support of her family, she found strength and learned to embrace her journey with peace. ? ?? Watch her inspiring story: https://lnkd.in/eM7X2uxi

Big missions require bold teams. At PharmaEssentia, we’re searching for passionate, talented individuals to help us revolutionize care for myeloproliferative neoplasms and other serious diseases. ? Here are a few of our open positions: ? ?? Director, Market Access Marketing: https://lnkd.in/eJupP3Fd ?? Director, Medical and Scientific Communications: https://lnkd.in/eQFzEewT ?? Head of Commercial Analytics and Insights: https://lnkd.in/eSSpBq8p ? Check out our career page to view our full list: https://lnkd.in/eE2HJxPX